Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
RVPH
$0.2207
$
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
Next Earnings
2026-02-25
Beta
0.044
Average Volume
Market Cap
Last Dividend
CIK
0001742927
ISIN
US76152G1004
CUSIP
76152G100
CEO
Laxminarayan Bhat
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
14
IPO Date
2018-10-18
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum | CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Sachs 9th Annual Neuroscience Innovation Forum, taking place January 11, 2026, in San Francisco, CA. | GlobeNewsWire | 2025-12-29 08:00:00 |
| Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Rating of “Moderate Buy” by Analysts | Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a | Defense World | 2025-12-27 02:30:42 |
| FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug | Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) on Tuesday announced a regulatory update following a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA). | Benzinga | 2025-12-23 09:26:44 |
| Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia | Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of schizophrenia | GlobeNewsWire | 2025-12-23 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 8-K | 2026-01-23 | 2026-01-23 | View Filing |
| SC 13G/A | 2026-01-16 | 2026-01-16 | View Filing |
| 8-K | 2025-12-23 | 2025-12-23 | View Filing |
| SC 13D/A | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-19 | 2025-12-19 | View Filing |
| 4 | 2025-12-19 | 2025-12-19 | View Filing |
| 4 | 2025-12-19 | 2025-12-19 | View Filing |
| 4 | 2025-12-19 | 2025-12-19 | View Filing |
| 25-NSE | 2025-12-12 | 2025-12-12 | View Filing |
| DEFA14A | 2025-12-05 | 2025-12-05 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| ARS | 2025-11-04 | 2025-11-04 | View Filing |
| DEFA14A | 2025-11-04 | 2025-11-04 | View Filing |
| DEF 14A | 2025-11-04 | 2025-11-04 | View Filing |
| PRE 14A | 2025-10-24 | 2025-10-24 | View Filing |
| 8-K | 2025-10-17 | 2025-10-17 | View Filing |
| SC 13G | 2025-09-29 | 2025-09-29 | View Filing |
| 8-K | 2025-09-26 | 2025-09-26 | View Filing |
| SC 13D/A | 2025-09-24 | 2025-09-24 | View Filing |
| SC 13D/A | 2025-09-24 | 2025-09-24 | View Filing |
| 8-K | 2025-09-19 | 2025-09-19 | View Filing |
| 424B5 | 2025-09-19 | 2025-09-19 | View Filing |
| 424B5 | 2025-09-18 | 2025-09-18 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13D/A | 2025-07-01 | 2025-07-01 | View Filing |
| SC 13D/A | 2025-07-01 | 2025-07-01 | View Filing |
| SC 13G | 2025-07-01 | 2025-07-01 | View Filing |
| 8-K | 2025-06-26 | 2025-06-26 | View Filing |
| 424B5 | 2025-06-26 | 2025-06-26 | View Filing |
| 424B5 | 2025-06-25 | 2025-06-25 | View Filing |
| 8-K | 2025-06-06 | 2025-06-06 | View Filing |
| 8-K | 2025-06-02 | 2025-06-02 | View Filing |
| 424B5 | 2025-05-30 | 2025-05-30 | View Filing |
| 8-K | 2025-05-30 | 2025-05-30 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-15 | 2025-05-15 | View Filing |
| S-8 | 2025-04-03 | 2025-04-03 | View Filing |
| 10-K | 2025-04-03 | 2025-04-02 | View Filing |
| NT 10-K | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-07 | 2025-02-07 | View Filing |
| SC 13D/A | 2025-01-31 | 2025-01-31 | View Filing |
| SC 13G | 2024-12-23 | 2024-12-23 | View Filing |
| SC 13D/A | 2024-12-20 | 2024-12-20 | View Filing |
| 424B5 | 2024-12-18 | 2024-12-18 | View Filing |
| 8-K | 2024-12-18 | 2024-12-17 | View Filing |
| 424B5 | 2024-12-16 | 2024-12-16 | View Filing |
| 8-K | 2024-12-16 | 2024-12-16 | View Filing |
| 8-K | 2024-12-12 | 2024-12-12 | View Filing |
| 4 | 2024-12-12 | 2024-12-12 | View Filing |
| 4 | 2024-12-12 | 2024-12-12 | View Filing |
| 4 | 2024-12-12 | 2024-12-12 | View Filing |
| 4 | 2024-12-12 | 2024-12-12 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| ARS | 2024-10-28 | 2024-10-28 | View Filing |
| DEF 14A | 2024-10-28 | 2024-10-28 | View Filing |
| PRE 14A | 2024-10-17 | 2024-10-17 | View Filing |
| 8-K | 2024-09-17 | 2024-09-17 | View Filing |
| 4 | 2024-09-17 | 2024-09-17 | View Filing |
| 4 | 2024-09-17 | 2024-09-17 | View Filing |
| SC 13D/A | 2024-08-23 | 2024-08-23 | View Filing |
| SC 13D/A | 2024-08-23 | 2024-08-23 | View Filing |
| 8-K/A | 2024-08-22 | 2024-08-22 | View Filing |
| 424B5 | 2024-08-22 | 2024-08-22 | View Filing |
| 8-K | 2024-08-21 | 2024-08-21 | View Filing |
| SC 13G | 2024-08-14 | 2024-08-14 | View Filing |
| 10-Q | 2024-08-14 | 2024-08-14 | View Filing |
| 8-K | 2024-08-14 | 2024-08-14 | View Filing |
| 8-K | 2024-07-09 | 2024-07-09 | View Filing |
| SC 13D/A | 2024-05-31 | 2024-05-31 | View Filing |
| 8-K | 2024-05-29 | 2024-05-29 | View Filing |
| 424B5 | 2024-05-29 | 2024-05-28 | View Filing |
| S-8 | 2024-05-17 | 2024-05-17 | View Filing |
| 8-K | 2024-05-15 | 2024-05-15 | View Filing |
| 10-Q | 2024-05-14 | 2024-05-14 | View Filing |
| 8-K | 2024-05-14 | 2024-05-14 | View Filing |
| 8-K | 2024-04-15 | 2024-04-15 | View Filing |
| 10-K | 2024-04-15 | 2024-04-15 | View Filing |
| 8-K | 2024-04-15 | 2024-04-15 | View Filing |
| 8-K | 2024-04-15 | 2024-04-15 | View Filing |
| NT 10-K | 2024-04-02 | 2024-04-02 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Pivot Points Strategy | 17.65% | 0.97 | 18 | 0.6 | 0.32 | 15.6 |
| Neural Forcast | 16.97% | 1.1 | 20 | 0.84 | 0.74 | 14.92 |
| Quantum Inspired Strategy | 16.60% | 0.97 | 16 | 0.51 | 0.27 | 14.55 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | x | xxxx | xxxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | x | xxxx | xxxxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xx |
| xxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxx | x% | x | xx | x | x | xx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |